$20.76
0.442.17%
Últ. Act.: Oct 29, 4:42 PM
Acadia Pharmaceuticals (ACAD) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Acadia Pharmaceuticals (ACAD) publicó su última previsión de agosto 4, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $1.24B - $1.3B para el período.
En comparación con la previsión anterior, Acadia Pharmaceuticals elevado redujo su previsión de ingresos desde un rango anterior de $1.22B - $1.28B.
Acadia Pharmaceuticals ha emitido 15 actualizaciones de orientación entre el noviembre 2, 2022 y el agosto 4, 2026. During this period, the company raised its outlook 6 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.04 | $0.07 | $0.13 | $0.14 |
| Actual | $0.18 | $0.02 | $0.14 | $0.26 |
| Surprise | +350.0% | -71.4% | +7.69% | +85.7% |
| Revenue | ||||
| Estimate | $295.2M | $280.6M | $292.5M | $275.4M |
| Actual | $308.0M | $268.1M | $284.0M | $278.6M |
| Surprise | +4.31% | -4.48% | -2.92% | +1.19% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.19 | $0.22 | $0.18 | $0.20 |
| Revenue | ||||
| Consensus | $333.0M | $362.1M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $0.18 | $0.04 | 350.0 % |
| Q1 | May 6, 2026 | $0.02 | $0.07 | -71.4 % |
| Q4 | Feb 25, 2026 | $0.14 | $0.13 | 7.69 % |
| Q3 | Nov 5, 2025 | $0.26 | $0.14 | 85.7 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $307.96M | $295.22M | 4.31 % |
| Q1 | May 6, 2026 | $268.06M | $280.65M | -4.48 % |
| Q4 | Feb 25, 2026 | $283.99M | $292.52M | -2.92 % |
| Q3 | Nov 5, 2025 | $278.63M | $275.36M | 1.19 % |